SARC

Our goal is to achieve breakthroughs in sarcoma research that help improve patient outcomes, and ultimately lead to a cure.

Find a SARC Study

View SARC clinical trials

Resources for Researchers

Biospecimens, Clinical Data

Who we are

Meet our experts

SARC FUNDING

LEARN HOW TO APPLY

Kirsch Mowery 2015

DAVID KIRSCH, MD, PHD
YVONNE MOWERY, MD, PHD
Duke University Medical Center
Mechanisms that Regulate Sarcoma Response to Immune Checkpoint Inhibition of PD1

Read more about Kirsch Mowery 2015
Log in to post comments

Man 2015

TSZ KWONG “CHRIS” MAN, PHD
Baylor College of Medicine
The Metastatic Role of Lysyl Oxidase in Osteosarcoma

Read more about Man 2015
Log in to post comments

Tseng 2015

WILLIAM W. TSENG, MD
University of Southern California
Immune Profiling in Well Differentiated/Dedifferentiated Liposarcoma

Read more about Tseng 2015
Log in to post comments

Rhabdomyosarcoma Cohort Open for Accrual to SARC024 Regorafenib

SARC024 is a blanket protocol exploring the potential clinical benefit of regorafenib in several different subtypes of sarcoma. Three cohorts or patient groups have completed accrual including osteosarcoma, lipsosarcoma and Ewing sarcoma. Recently, a cohort to include patients with metastatic or recurrent rhabdomyosarcoma has been activated.

MEET THE PEOPLE OF SARC

Denise Reinke, President & CEO

Denise Reinke has been with SARC since its inception in 2002 assuming increasing responsibilities over the years. She is uniquely positioned to lead SARC as President and CEO given her sarcoma nurse practitioner, clinical trials, pharmaceutical and business experience.

Read full bio

See all bios

SARC - Sarcoma Alliance for Research Through Collaboration, Ann Arbor

Kirsch Mowery 2015

Man 2015

Tseng 2015

Pages

Where can I find a sarcoma specialist?

Financial Contributions

Rhabdomyosarcoma Cohort Open for Accrual to SARC024 Regorafenib

MEET THE PEOPLE OF SARC